Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-11-04

Clinical Trial Update: Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating BB3 for treatment of myocardial infarction was terminated, and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BB3

Snippet

Sponsor: Angion Biomedica Corp | Conditions: Myocardial Infarction | Phase 2 | Status: TERMINATED | Results posted: 2014-11-04